GODDYN advised Celyad on agreement with Horizon Discovery

GODDYN has advised Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based therapies, on an exclusive agreement with Horizon Discovery Group plc (LSE: HZD), for the use of Horizon Discovery’s shRNA technology to generate Celyad’s second non-gene-edited allogeneic platform.

Follow this link to download Celyad’s press release from Celyad’s website (external link).